EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results

Aristides K Maniatis, Paul S Thornton, Ulhas M Nadgir, Elpis Vlachopapadopoulou, Oleg Malievskiy, Elena M Aghajanova, Maria Korpal-Szczyrska, Katie A Woods, Meng Mao, Carol Zhao, Sohair G Abdelrahman, Eric A Huang und 3 weitere

Hormone Research in Paediatrics · 2025

DOI: 10.1159/000545064 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hormone Research in Paediatrics, 2025. Verfasst von Aristides K Maniatis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Rocky Mountain Pediatric Endocrinology, Centennial, Colorado, USA. Hauptthemen laut MEDLINE: Body Height, Dwarfism, Pituitary, Growth Disorders, Human Growth Hormone. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This international, Phase 3, open-label extension trial evaluated the long-term safety and efficacy of once-weekly lonapegsomatropin in children with growth hormone deficiency (GHD).

Methods

Conducted across 63 sites (15 countries), the enliGHten trial enrolled children with GHD who previously participated in a Phase 3 lonapegsomatropin trial (heiGHt or fliGHt). Participants received subcutaneous injections of lonapegsomatropin dosed at 0.24 mg hGH/kg/week. Safety was monitored through adverse events, local tolerability, hormone levels, and metabolic parameters. Efficacy was evaluated through annualized height velocity (AHV), change in height standard deviation score (SDS), and IGF-1 SDS.

Results

Lonapegsomatropin demonstrated sustained efficacy with mean height SDS (−0.39 at year 4, n = 298) approaching the mean for children of average stature (height SDS = 0) over time. Eighty-one participants completed treatment for pediatric GHD during the trial, and 48 (59.3%) of these met or exceeded their average parental height SDS at their last visit. For the full population, mean values of weekly average IGF-1 remained within 0–2 SDS throughout the trial. Growth was maintained throughout pubertal development and the dose remained stable throughout the trial. Adverse events were mostly mild or moderate and remained consistent with prior reports of daily somatropin with no evidence of accelerated skeletal maturation or safety signals associated with anti-drug antibodies.

Conclusion

Treatment of pediatric GHD with lonapegsomatropin in the enliGHten trial provided robust growth outcomes and maintained a safety profile comparable to that of daily GH in a population with a broad range of pubertal statuses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body HeightDwarfism, PituitaryGrowth DisordersHuman Growth HormoneAdolescentChildChild, PreschoolFemaleHumansMaleInsulin-Like Growth Factor I

Stichwörter der Autor:innen

Final adult heightLong-acting growth hormonePediatric growth hormone deficiency

Substanzen

Human Growth HormoneInsulin-Like Growth Factor Ilonapegsomatropin

Autor:innen und Institutionen

  • Rocky Mountain Pediatric Endocrinology, Centennial, Colorado, USA.
  • Cook Children's Medical Center, Fort Worth, Texas, USA.
  • Pediatric Endocrinology, Sutter Health, Sacramento, California, USA.
  • Children's Hospital. P. A. Kyriakou, Athens, Greece.
  • Department of Pediatrics, Bashkir State Medical University, Ufa, Russian Federation.
  • Department of Endocrinology, Yerevan State Medical University, Yerevan, Armenia.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Maniatis, A. K., Thornton, P. S., Nadgir, U. M., Vlachopapadopoulou, E., Malievskiy, O., Aghajanova, E. M., Korpal-Szczyrska, M., Woods, K. A., Mao, M., Zhao, C., Abdelrahman, S. G., Huang, E. A., Komirenko, A. S., Shu, A. D., & Hofman, P. (2025). Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results. Hormone Research in Paediatrics. https://doi.org/10.1159/000545064

Vancouver

Maniatis AK, Thornton PS, Nadgir UM, Vlachopapadopoulou E, Malievskiy O, Aghajanova EM, et al. Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results. Hormone Research in Paediatrics. 2025. doi:10.1159/000545064

BibTeX
@article{Maniatis2025,
  author = {Maniatis, Aristides K and Thornton, Paul S and Nadgir, Ulhas M and Vlachopapadopoulou, Elpis and Malievskiy, Oleg and Aghajanova, Elena M and Korpal-Szczyrska, Maria and Woods, Katie A and Mao, Meng and Zhao, Carol and Abdelrahman, Sohair G and Huang, Eric A and Komirenko, Allison S and Shu, Aimee D and Hofman, Paul},
  title = {Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results},
  journal = {Hormone Research in Paediatrics},
  year = {2025},
  doi = {10.1159/000545064}
}
Kostenlos starten →